title: [Studies on vaccination schedule of inactivated hepatitis A vaccine].
abstract: OBJECTIVE
  To evaluate three vaccination schedules of inactivated hepatitis A vaccine in rhesus monkeys (Macaca Mulatta).
  
  
  METHODS
  Seventeen rhesus monkeys were divided randomly into four groups. The first group of five monkeys was immunized with vaccination schedule 1 (one immunization at week 0); The second group of five monkeys was immunized with vaccination schedule 2 (first injection at week 0, and booster one at week 4); the third group of five monkeys was immunized with vaccination schedule 3 (first injection at week 0, and booster one at week 24); and the fourth group of two monkeys with MEM as control. Rhesus monkeys were inoculated by intramuscular injections to detect the ALT (alanine aminotransferase), liver pathology and anti-HAV at different time.
  
  
  RESULTS
  During the 52-week observation, no abnormal elevation of ALT or liver pathology appeared. The IgG response for vaccination schedule 1 reached the highest level (13 219 mIU/ml), and decreased gradually to 2 056 mIU/ml at week 52. After booster immunization at week 4, the IgG response for vaccination schedule 2 was 13 863 mIU/ml at week 12, and decreased to 6 285 mIU/ml. The highest level of IgG (40 638 mIU/ml) for vaccination schedule 3 appeared at week 28 after booster injection at week 24. Further more, at week 52 the IgG level for vaccination schedule 3 was also the highest among the three vaccination schedules.
  
  
  CONCLUSIONS
  The inactivated hepatitis A vaccine is safe and well immunogenic. The vaccination schedule 3 showed the best immune response among the three vaccination schedules.
authors.affiliation: Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650107, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Hu
authors.forename: S
authors.initials: S
authors.lastname: Tan
authors.forename: W
authors.initials: W
authors.lastname: Jin
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D002460:Cell Line; D006506:Hepatitis A / Q000276:immunology / Q000517:prevention & control*; D022362:Hepatitis A Vaccines / Q000008:administration & dosage / Q000276:immunology*; D030041:Hepatitis A virus / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000187:drug effects / Q000276:immunology; D007273:Injections, Intramuscular; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008253:Macaca mulatta; D008297:Male; D013997:Time Factors; D016896:Treatment Outcome; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology
chemical_list: D022362:Hepatitis A Vaccines; D007074:Immunoglobulin G; D015164:Vaccines, Inactivated; D000410:Alanine Transaminase